Delivery of the SRT-100 marks the expansion of radiotherapy services at Dublin’s Beacon Hospital
Non-melanoma skin cancer affects more than 12,000 patients in Ireland annually
BOCA RATON, Fla., July 25, 2023 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, has installed the first SRT-100™ System in Ireland at Dublin’s Beacon Hospital. The system will provide a highly efficacious and non-invasive solution to treat the growing numbers of non-melanoma skin cancer patients in Ireland, which is estimated by the Irish Cancer Society to number 12,000 annually and growing.
Siobhra O’Sullivan, M.D., lead radiation oncologist at Beacon Hospital said, “We are delighted to announce expansion of our radiotherapy services at Beacon Hospital, Dublin, with the delivery of the Sensus SRT-100. This new unit allows us to provide non-surgical superficial radiotherapy treatments for patients with non-melanoma skin cancers, such as squamous cell carcinoma and basal cell carcinoma, and will also be used in the management of keloid scars.
“At Beacon Hospital, our skin cancer services are provided by a multidisciplinary team of radiation oncologists, plastic surgeons, dermatologists, and medical oncologists, to provide patients we serve with the most advanced and proven treatments. The SRT-100 is an exciting addition to our hospital, and we are delighted to be the first facility in Ireland with this unit.”
Dr. O’Sullivan added, “We would like to thank the Sensus team for a seamless install, which resulted in minimal disruption to our busy department, and we look forward to treating our first patients very soon!”
Commenting on the sale, Joe Sardano, chairman and chief executive officer of Sensus Healthcare, said, “We are thrilled to generate our first sale of an SRT System in Ireland and to a leading, technologically savvy facility such as Beacon Hospital. Beacon will serve as an example to the Irish dermato-oncology community of innovation in patient care. We expect that this system will be the first of many placed not only in Ireland, but in the United Kingdom as well.”
About Beacon Hospital
Located in Sandyford, South Dublin, Beacon Hospital is one of the most technologically advanced private hospitals in all of Europe.
With 181 inpatients beds, 70 day-case beds, eight operating theatres, two cath labs, four endoscopy suites, over 1600 healthcare professionals and upwards of 300 consultants, Beacon Hospital operates as a full-service acute hospital. Departments include, but are not limited to; Cancer Care, Cardiology, Cardiothoracic Surgery, Dermatology, Emergency Medicine, Endocrinology, Endoscopy, ENT, General Medicine and Surgery, Intensive Care, Neurology & Neurosurgery, Orthopaedics, Physiotherapy, Paediatric Care (medical & surgical), Plastic Surgery, Radiology, Rheumatology, Sports Medicine, Urology, Vascular Services, Women’s Health and Men’s Health and more.
Beacon Hospital treated over 207,000 patients last year across all areas of medicine and surgery. Click here to read more about Beacon Hospital’s Department’s and Services.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ‘forward-looking statements.’ In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to return to profitability; our ability to sell the number of SRT units we anticipate for the balance of 2023; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
To date, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty have not had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
